Adcytherix
Updated: November 16, 2025
CEO - Jack Elands
Country: France | Funding: €135M (+)
Founded: 2023
Website: https://www.adcytherix.com
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
Founded: 2023
Website: https://www.adcytherix.com
Adcytherix is dedicated to creating and advancing innovative antibody-drug conjugates (ADCs) that go beyond current limitations. By combining state-of-the-art payload innovation with deep ADC development expertise, the company aims to revolutionize targeted therapies for cancer and other conditions of significant unmet medical need. Most existing ADCs rely on two classes of payloads, tubulin and topoisomerase 1 inhibitors. Adcytherix is investigating novel payloads classes with mechanisms of action selected to overcome tumor resistance while enhancing safety, with the potential to manage a wider range of cancers. Adcytherix is guided by a experienced management team and is backed by a network of top-tier experts in the field of ADC development.
